Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

• Drug: PF-04447943
  
  3 mg solution, oral single dose.
• Drug: PF-04447943
  
  10 mg solution, oral single dose.
• Drug: PF-04447943
  
  25 mg solution, oral single dose.
• Drug: Placebo
  
  Solution, oral single dose.
• Drug: PF-04447943
  
  25 mg solution, oral twice daily for 7 days.
• Drug: Placebo
  
  Solution, oral twice daily for 7 days.

• Experimental: Single dose
  
  3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
  Interventions:
  

  • Drug: PF-04447943
  • Drug: PF-04447943
  • Drug: PF-04447943
  • Drug: Placebo
• Experimental: Multiple dose
  
  3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
  Interventions:
  

  • Drug: PF-04447943
  • Drug: Placebo

Inclusion Criteria:

• For young cohort, healthy male and/or female Japanese of non-child bearing potential between the age of 18 and 55 years, inclusive.
• For elderly cohort, healthy male and/or female Japanese of non-child bearing potential between the age of 65 and 85 years, inclusive.
• Body Mass Index (BMI) between 17.5 to 30.5 kg/m2, and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Pregnant or nursing women; women of childbearing potential.
• Males who are unwilling to abstain from sexual intercourse or use a condom with all child-bearing potential women for the duration of the study.